Cinanserin

Cinanserin
Clinical data
Other names	SQ-10643; SQ10643; NSC-125717; NSC125717
Drug class	Serotonin 5-HT2 receptor antagonist; Serotonin 5-HT2A receptor antagonist
ATC code	None;
Identifiers
	IUPAC name (2E)-N-(2-{[3-(dimethylamino)propyl]thio}phenyl)-3-phenylacrylamide;
CAS Number	1166-34-3 ;
PubChem CID	5475158;
ChemSpider	4584027 ;
UNII	KI6J9OY7A3;
ChEBI	CHEBI:145999;
ChEMBL	ChEMBL18786 ;
CompTox Dashboard (EPA)	DTXSID30859588 DTXSID7045653, DTXSID30859588 ;
ECHA InfoCard	100.220.552
Chemical and physical data
Formula	C20H24N2OS
Molar mass	340.49 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)CCCSC1=CC=CC=C1NC(=O)\C=C\C2=CC=CC=C2;
	InChI InChI=1S/C20H24N2OS/c1-22(2)15-8-16-24-19-12-7-6-11-18(19)21-20(23)14-13-17-9-4-3-5-10-17/h3-7,9-14H,8,15-16H2,1-2H3,(H,21,23)/b14-13+ ; Key:RSUVYMGADVXGOU-BUHFOSPRSA-N ;
	(what is this?) (verify)

Cinanserin (INNTooltip International Nonproprietary Name; developmental code name SQ-10643) is a serotonin 5-HT_2A and 5-HT_2C receptor antagonist which was discovered in the 1960s and was never marketed. It has about 50-fold higher affinity for the 5-HT_2A receptor than for 5-HT_2C, and very low affinity for 5-HT₁ receptors. The drug also inhibits the 3C-like protease of SARS-CoV-1 and SARS-CoV-2, but with much lower affinity.